DiscoveRx

DiscoverRx develops, commercializes and manufactures reagents and assay kits for the [...] discovery market. Their focus is on lucrative protein target classes, such as G-protein-coupled receptors and kinases.

The company is built around a proprietary technology called enzyme fragment complementation or EFC which forms the basis of the assays that they design and market. In EFC, two β-galactosidase fragments are employed which are themselves inactive. One fragment (EA) has an inactivating deletion while the second fragment (ED) has a complementing fragment; in solution where both EA and ED are present, the fragments combine and active β-gal tetramers form spontaneously.